Evidence map›Paper›PMID 27793045›Full record

ArticleOncotarget2016

Serpin E2 promotes breast cancer metastasis by remodeling the tumor matrix and polarizing tumor associated macrophages.

Tatiana Smirnova, Laura Bonapace, Gwen MacDonald, Shunya Kondo, Jeffrey Wyckoff, Hilmar Ebersbach, Bérengère Fayard, Arno Doelemeyer, Marie-May Coissieux, Marinus R Heideman and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Multidimensional Imaging of Breast Cancer.Cold Spring Harbor perspectives in medicine · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Tatiana SmirnovaFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Laura BonapaceFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Gwen MacDonaldFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Shunya KondoFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Jeffrey WyckoffFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Hilmar EbersbachNovartis Institute for Biomedical Research, Basel, Switzerland.
Bérengère FayardFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Arno DoelemeyerNovartis Institute for Biomedical Research, Basel, Switzerland.
Marie-May CoissieuxFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Marinus R HeidemanFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Mohamed Bentires-AljFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Nancy E HynesFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Friedrich Miescher Institute · CHNovartis (Switzerland) · CHMassachusetts Institute of Technology · USUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The extracellular serine protease inhibitor serpinE2 is overexpressed in breast cancer and has been shown to foster metastatic spread. Here, we investigated the hypothesis that serpinE2 creates tumor-promoting conditions in the tumor microenvironment (TME) by affecting extracellular matrix remodeling. Using two different breast cancer models, we show that blocking serpinE2, either by knock-down (KD) in tumor cells or in response to a serpinE2 binding antibody, decreases metastatic dissemination from primary tumors to the lungs. We demonstrate that in response to serpinE2 KD or antibody treatment there are dramatic changes in the TME. Multiphoton intravital imaging revealed deposition of a dense extracellular collagen I matrix encapsulating serpinE2 KD or antibody-treated tumors. This is accompanied by a reduction in the population of tumor-promoting macrophages, as well as a decrease in chemokine ligand 2, which is known to affect macrophage abundance and polarization. In addition, TIMP-1 secretion is increased, which may directly inhibit matrix metalloproteases critical for collagen degradation in the tumor. In summary, our findings suggest that serpinE2 is required in the extracellular milieu of tumors where it acts in multiple ways to regulate tumor matrix deposition, thereby controlling tumor cell dissemination.

Indexed as

Cell MovementAnimalsAntineoplastic AgentsBreast NeoplasmsCell Line, TumorChemokine CCL2Collagen Type IExtracellular MatrixExtracellular Signal-Regulated MAP KinasesFemaleHumansLung NeoplasmsMacrophagesMice, Inbred BALB CMice, SCIDNeoplasm InvasivenessAntineoplastic AgentsCCL2 protein, humanChemokine CCL2Collagen Type IExtracellular Signal-Regulated MAP KinasesSerpin E2SERPINE2 protein, humanSerpine2 protein, mouseTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1breast cancercollagen Imetastasisserine protease inhibitorstumor associated macrophages

Identifiers

PMID27793045
PMCPMC5347692
OpenAlexW2540980010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.